Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Phase I/II Study of Adoptive Immunotherapy With CD8+ Proteinase 3 (Myeloblastin)-Specific CTL Clones for HLA-A2+ Patients With Relapse or Progression of Disease After Allogeneic Hematopoietic Stem Cell Transplant for High Risk Myeloid Leukemias

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT00052598
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:36:17.454063+00:00
Published At
2017-02-15T00:00:00+00:00
Record Updated At
2017-02-15
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Accelerated Phase Chronic Myelogenous Leukemia", "Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Blastic Phase Chronic Myelogenous Leukemia", "Childhood Chronic Myelogenous Leukemia", "Childhood Myelodysplastic Syndromes", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Relapsing Chronic Myelogenous Leukemia", "Secondary Acute Myeloid Leukemia"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2017-02-15"
protocolSection.identificationModule.nctId
"NCT00052598"
protocolSection.identificationModule.officialTitle
"Phase I/II Study of Adoptive Immunotherapy With CD8+ Proteinase 3 (Myeloblastin)-Specific CTL Clones for HLA-A2+ Patients With Relapse or Progression of Disease After Allogeneic Hematopoietic Stem Cell Transplant for High Risk Myeloid Leukemias"
protocolSection.statusModule.overallStatus
"TERMINATED"
protocolSection.designModule.phases
["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Accelerated Phase Chronic Myelogenous Leukemia (protocolSection.conditionsModule.conditions)
  • Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome (protocolSection.conditionsModule.conditions)
  • Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities (protocolSection.conditionsModule.conditions)
  • Adult Acute Myeloid Leukemia With Del(5q) (protocolSection.conditionsModule.conditions)
  • Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) (protocolSection.conditionsModule.conditions)
  • Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) (protocolSection.conditionsModule.conditions)
  • Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) (protocolSection.conditionsModule.conditions)
  • Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) (protocolSection.conditionsModule.conditions)
  • Blastic Phase Chronic Myelogenous Leukemia (protocolSection.conditionsModule.conditions)
  • Childhood Chronic Myelogenous Leukemia (protocolSection.conditionsModule.conditions)
  • Childhood Myelodysplastic Syndromes (protocolSection.conditionsModule.conditions)
  • Recurrent Adult Acute Myeloid Leukemia (protocolSection.conditionsModule.conditions)
  • Recurrent Childhood Acute Myeloid Leukemia (protocolSection.conditionsModule.conditions)
  • Relapsing Chronic Myelogenous Leukemia (protocolSection.conditionsModule.conditions)
  • Secondary Acute Myeloid Leukemia (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.